Meeting
2014 ASCO Annual Meeting
Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy.
Authors
Tomonori Hirashima
Department of Thoracic Malignancy, Osaka Prefectural Hospital Organization Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan
Tomonori Hirashima , Koichi Azuma , Nobuyuki Yamamoto , Toshiaki Takahashi , Makoto Nishio , Taizo Hirata , Kaoru Kubota , Kazuo Kasahara , Toyoaki Hida , Hiroshige Yoshioka , Kohei Suzuki , Shiro Akinaga , Kazuto Nishio , Tetsuya Mitsudomi , Kazuhiko Nakagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01580735
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8052)
DOI
10.1200/jco.2014.32.15_suppl.8052
Abstract #
8052
Poster Bd #
233
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
First Author: Akito Hata
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2018 ASCO Annual Meeting
Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer.
First Author: Chul Kim